<DOC>
	<DOCNO>NCT02509923</DOCNO>
	<brief_summary>The purpose study evaluate pharmacokinetics pharmacodynamics Z-215 ( 10 mg , 20 mg , 40 mg ) , compare Rabeprazole Sodium ( 10 mg , 20 mg ) Healthy Male Subjects . And evaluate food-effect Healthy Male Subjects administrate Z-215 20 mg .</brief_summary>
	<brief_title>To Evaluate Pharmacokinetics Pharmacodynamics Z-215 Healthy Male Subjects</brief_title>
	<detailed_description />
	<mesh_term>Rabeprazole</mesh_term>
	<criteria>Has negative result H. pylori IgG antibody screen . A body mass index 18.5≦BMI &lt; 25.0 kg/m^2 screening . Able understand consent study comply study . Able give inform consent write participate study . Has history PPI allergy . Has history drug food serious allergy . Presently history disease may affect evaluation study result gastrointestinal , hepatic , renal , respiratory , endocrine , blood , cardiovascular , mental congenial metabolic disease . Has history surgery ( resection liver , kidney , digestive tract ) may affect pharmacokinetics study drug . History previous current acidrelated disease . Received H. pylori eradication treatment within 6 month screen . Has 450msec &lt; QTC Fridericia test screen ECG . Has hypoacidity anacidity . Or determine low gastric acid stomach acid gastric pH monitoring baseline period . History suspicion drug , opioid , alcohol abuse positive screening result . Use prescription drug within 4 week prior baseline period . Use overthecounter drug within 2 week prior baseline period . Received blood transfusion within 12 week donate ≥400mL whole blood within 12 week ≥200mL whole blood within 4 week prior baseline period . Donated platelet plasma within 2 week prior baseline period .</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Male Subjects</keyword>
</DOC>